(19)
(11) EP 4 680 224 A1

(12)

(43) Date of publication:
21.01.2026 Bulletin 2026/04

(21) Application number: 24771709.3

(22) Date of filing: 14.03.2024
(51) International Patent Classification (IPC): 
A61K 31/343(2006.01)
A61K 9/08(2006.01)
 A61K 9/00(2006.01)
(52) Cooperative Patent Classification (CPC):
Y02A 50/30; A61K 31/343; A61P 33/02; A61K 31/496; A61K 45/06; A61K 2300/00
 
C-Sets:
  1. A61K 31/496, A61K 2300/00;
  2. A61K 31/343, A61K 2300/00;
(86) International application number:
PCT/US2024/019858
(87) International publication number:
WO 2024/192209 (19.09.2024 Gazette 2024/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 16.03.2023 US 202363452565 P

(71) Applicant: Vida Pharmacal, Inc.
Spring Branch, TX 78070 (US)

(72) Inventors:
  • MADIGAN, Roy
    Spring Branch, TX 78070 (US)
  • PANIZ-MONDOLFI, Alberto
    Spring Branch, TX 78070 (US)

(74) Representative: Lavoix 
Bayerstraße 83
80335 München
80335 München (DE)

   


(54) COMPOSITION AND METHOD FOR TREATING LEISHMANIASIS